Vagitocin® is a developmental pharmaceutical preparation for the treatment of vaginal atrophy. The product is based on oxytocin, a natural substance, which is produced in the body and that has been used to promote labour and breast-feeding since the beginning of the 1960ies.
Local application of Vagitocin® in the vagina has been shown to rejuvenate the vaginal mucosa. Vagitocin® is in clinical development phase 2. However, the development of Vagitocin® has been put on hold until a better understanding of its mechanism of action has been gained.
Learn more about oxytocin, vaginal atrophy and clinical development.
NOTE! Vagitocin® is not yet approved as a drug
